company background image
RVU logo

Ryvu Therapeutics WSE:RVU Stock Report

Last Price

zł55.50

Market Cap

zł1.3b

7D

-3.3%

1Y

-7.7%

Updated

27 Mar, 2024

Data

Company Financials +

Ryvu Therapeutics S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ryvu Therapeutics
Historical stock prices
Current Share Pricezł55.50
52 Week Highzł72.40
52 Week Lowzł53.50
Beta0.61
1 Month Change-5.77%
3 Month Change-7.04%
1 Year Change-7.65%
3 Year Change-4.31%
5 Year Change-13.82%
Change since IPO927.78%

Recent News & Updates

Recent updates

Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

Oct 20
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Aug 02
We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?

Jan 25
Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?

What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?

Feb 05
What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?

Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return

Dec 14
Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return

Shareholder Returns

RVUPL Life SciencesPL Market
7D-3.3%-1.8%2.3%
1Y-7.7%-17.1%35.3%

Return vs Industry: RVU exceeded the Polish Life Sciences industry which returned -16% over the past year.

Return vs Market: RVU underperformed the Polish Market which returned 35.7% over the past year.

Price Volatility

Is RVU's price volatile compared to industry and market?
RVU volatility
RVU Average Weekly Movement3.1%
Life Sciences Industry Average Movement6.3%
Market Average Movement5.0%
10% most volatile stocks in PL Market9.5%
10% least volatile stocks in PL Market3.2%

Stable Share Price: RVU has not had significant price volatility in the past 3 months.

Volatility Over Time: RVU's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007270Pawel Przewiezlikowskihttps://www.ryvu.com

Ryvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company’s products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia.

Ryvu Therapeutics S.A. Fundamentals Summary

How do Ryvu Therapeutics's earnings and revenue compare to its market cap?
RVU fundamental statistics
Market capzł1.28b
Earnings (TTM)-zł92.11m
Revenue (TTM)zł67.30m

19.1x

P/S Ratio

-13.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RVU income statement (TTM)
Revenuezł67.30m
Cost of Revenuezł17.55m
Gross Profitzł49.74m
Other Expenseszł141.85m
Earnings-zł92.11m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 15, 2024

Earnings per share (EPS)-3.98
Gross Margin73.92%
Net Profit Margin-136.88%
Debt/Equity Ratio3.5%

How did RVU perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.